EFNA3-MAP

EFNA3-MAP (ephrin-A3 mimetic agonist peptide) is a novel, nonsteroidal, nonhormonal peptide agonist designed to target and activate the ephrin type-A receptor 2 (EphA2). Developed by researchers at Stanford University and The Ohio State University, EFNA3-MAP mimics the activity of endogenous ephrin-A3 (EFNA3) to stimulate ephrin-Eph signaling pathways. This activation promotes the expression of desmosomal cadherins, specifically desmoglein-1 (DSG1) and desmocollin-1 (DSC1), thereby strengthening epithelial barriers and enhancing cell-cell adhesion. EFNA3-MAP is being investigated for multiple therapeutic applications, including accelerating re-epithelialization and preventing excessive granulation tissue in cutaneous wound healing (such as distal limb wounds in horses), restoring vaginal epithelial thickness and barrier function in conditions of estrogen deficiency (e.g., menopause or progestin-only contraceptive use), and improving skin barrier function in atopic dermatitis.

Other names

EFNA3 mimetic agonist peptideEFNA-3 mimetic agonist peptideEFNA 3 mimetic agonist peptideephrin A3 mimetic agonist peptideephrin-A3 mimetic agonist peptideephrin-A-3 mimetic agonist peptideephrin-A 3 mimetic agonist peptide